Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 10 (TRAJ10) is a specific joining (J) gene segment within the human T cell receptor (TCR) alpha (TRA) locus. TCRs are heterodimeric surface receptors on T lymphocytes responsible for recognizing antigenic peptides bound to major histocompatibility complex (MHC) molecules[1][2]. The diversity of antigen recognition is generated by somatic recombination of variable (V), joining (J), and constant (C) gene segments for the alpha chain. TRAJ10 is one of approximately 61 J segments available for recombination in the alpha chain locus, contributing to the hypervariable complementarity determining region 3 (CDR3) that directly binds the antigen–MHC complex[2][1]. By itself, TRAJ10 is not a therapeutic target, receptor, or protein but is a constituent gene element foundational for TCR repertoire diversity[1][2]. Key clarification: - TRAJ10 is a gene segment *within* the T cell receptor alpha locus, not a standalone protein or receptor. Its sole biological role is as a recombinatorial component of the TCR alpha chain in developing T lymphocytes, essential for proper immune functioning but not druggable or directly connected to any existing therapeutics or biomarker strategies[1][2]. If you are searching for information on the full T cell receptor or its therapeutic targeting, it may be more appropriate to look for "T cell receptor alpha/beta complex" or "TCR complex" as the canonical target entity[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 10 (TRAJ10).